CVR number 41102519
Industry 46.4610 Wholesale of pharmaceutical goods

1Point Pharma Aps

 

Quicksearch
from your own companies
Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...
Bankruptcy Risk 
2018
N/A
2019
N/A
2020
2021/6
2021
2022/6
2022
2023/6
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  0.0% 0.0% 29.4% 29.4% 21.0%  
Credit score (0-100)  0 0 1 1 4  
Credit rating  N/A N/A C C B  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 0.0  
How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2018
N/A
2019
N/A
2020
2021/6
2021
2022/6
2022
2023/6
Net sales  0 0 0 0 0  
Gross profit  0.0 0.0 0.0 0.0 -5.0  
EBITDA  0.0 0.0 0.0 0.0 -5.0  
EBIT  0.0 0.0 0.0 0.0 -5.0  
Pre-tax profit (PTP)  0.0 0.0 0.0 0.0 -8.4  
Net earnings  0.0 0.0 0.0 0.0 -8.4  
Pre-tax profit without non-rec. items  0.0 0.0 0.0 0.0 -8.4  
 
See the entire income statement

Balance sheet (kDKK) 
2018
N/A
2019
N/A
2020
2021/6
2021
2022/6
2022
2023/6
Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  0.0 0.0 40.0 40.0 31.6  
Interest-bearing liabilities  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  0.0 0.0 40.0 40.0 41.7  
Net Debt  0.0 0.0 0.0 0.0 0.0  
 
See the entire balance sheet

Volume 
2018
N/A
2019
N/A
2020
2021/6
2021
2022/6
2022
2023/6
Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  0.0 0.0 0.0 0.0 -5.0  
Gross profit growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Employees  0 0 0 0 0  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  0 0 40 40 42  
Balance sheet change%  0.0% 0.0% 0.0% 0.0% 4.3%  
Added value  0.0 0.0 0.0 0.0 -5.0  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 0 0 0 0  
Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  0.0 0.0 0.0 0.0 -1.0  

Profitability 
2018
N/A
2019
N/A
2020
2021/6
2021
2022/6
2022
2023/6
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  0.0% 0.0% 0.0% 0.0% 100.0%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  0.0% 0.0% 0.0% 0.0% -8.1%  
ROI %  0.0% 0.0% 0.0% 0.0% -9.2%  
ROE %  0.0% 0.0% 0.0% 0.0% -23.6%  

Solidity 
2018
N/A
2019
N/A
2020
2021/6
2021
2022/6
2022
2023/6
Equity ratio %  0.0% 0.0% 100.0% 100.0% 75.7%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  0.0% 0.0% 0.0% 0.0% 0.0%  
Gearing %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 0.0% 0.0% 0.0%  

Liquidity 
2018
N/A
2019
N/A
2020
2021/6
2021
2022/6
2022
2023/6
Quick Ratio  0.0 0.0 0.0 0.0 4.1  
Current Ratio  0.0 0.0 0.0 0.0 4.1  
Cash and cash equivalent  0.0 0.0 0.0 0.0 0.0  

Capital use efficiency 
2018
N/A
2019
N/A
2020
2021/6
2021
2022/6
2022
2023/6
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 365.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  0.0 0.0 40.0 40.0 31.6  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2018
N/A
2019
N/A
2020
2021/6
2021
2022/6
2022
2023/6
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 0 0  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 0 0  
EBIT / employee  0 0 0 0 0  
Net earnings / employee  0 0 0 0 0